Diabetes is a major risk factor for heart failure (HF). Patients with diabetes have a high incidence of both clinical HF and subclinical LV dysfunction. Although intensive glucose lowering does not appear to impact on HF outcomes, the choice of glucose-lowering agents plays an important role in the development of HF and related cardiovascular outcomes. Whilst metformin and insulin appear to have little impact on HF progression, the role of sulphonylurea agents in this patient population remains uncertain. Thiazolidinediones (TZDs) are associated with a significant risk of HF progression and are best avoided in patients at risk. The incretin-based therapies (GLP agonists and DPP-4 inhibitors) are generally not associated with any HF interaction. However, a small increase in HF admissions was observed with the DPP-4 inhibitor saxagliptin. The GLP-1 agonist liraglutide was recently shown to reduce cardiovascular and all-cause mortality, yet hospitalization for HF was not significantly reduced. The SGLT2 inhibitor empagliflozin was shown to reduce HF admissions and cardiovascular mortality in patients with prior cardiovascular disease including HF. These recent data showing improved outcomes with a glucose-lowering category provide a novel strategy to improve survival and reduce morbidity in diabetic patients at high cardiovascular disease risk.
Heart failure and diabetes
Diabetes is a major risk factor for the development of heart failure (HF) 1 . In the Framingham Study, men with diabetes had a 2.4-fold and women a five-fold increased risk of HF, a risk that was even greater when coronary heart disease was excluded. 2 Diabetes is encountered in 24-40% of patients with HF 3 , and in 30% of patients with HF and a preserved LVEF. 4 The prevalence of HF in patients with diabetes aged over 65 years has been reported to be as high as 22%. 5 Heart failure in a patient with diabetes is associated with a 3-year mortality of 40%, 10-fold that of an individual with diabetes and no HF. 6 Diabetes is also an important predictor of increased risk of hospitalization for HF. 7 Patients with diabetes have a 30% greater risk of requiring admission to hospital due to HF than those without diabetes. In patients with stable chronic HF, the co-existence of diabetes confers a three-fold greater rate of hospitalization for decompensated ventricular dysfunction. increased mortality and hospitalization rate for HF as those with diabetes. 8 Among HF patients in the CHARM trials programme, 9 the presence of diabetes and preserved EF conferred a higher risk of cardiovascular death or hospitalization for HF than in patients with reduced EF without diabetes. In more recent clinical trials, patients with diabetes admitted to hospital with HF had a high (23-30%) 3-year cardiovascular mortality.
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Left ventricular dysfunction and diabetes
Impaired LV diastolic function is observed using tissue Doppler imaging (TDI) in 40% of patients with diabetes. 12 Abnormalities of systolic function, despite a preserved EF in patients with diabetes, have been shown using TDI and 2-dimensional (2D) speckle tracking echocardiography (STE) in 43% of asymptomatic patients.
Abnormalities of myocardial function in patients with diabetes may occur in the absence of coronary heart disease. Several putative mechanisms may be responsible and include: micro-circulatory dysfunction, metabolic derangements with lipotoxicity, cytokine and renin-angiotension-aldosterone system (RAAS) activation, disturbed calcium handling, and endothelial dysfunction. 15 In addition, co-morbidities associated with diabetes, such as hypertension, dyslipidaemia, and renal impairment, result in both myocardial and coronary disease that increase the risk of HF. With the high incidence of subclinical cardiac dysfunction, patients with diabetes may develop HF with only a modest increase in fluid retention or further alteration of cardiac function.
Current cardiovascular outcome trials for glucose-lowering agents
Following publication of a meta-analysis suggesting that rosiglitazone increased the risk of myocardial infarction, the Food and Drug Administration (FDA) introduced requirements for cardiovascular safety trials of new glucose-lowering agents. The primary endpoint of these safety trials is major adverse cardiac event (MACE) outcomes including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Heart failure endpoints were not included in the primary endpoint, despite hospitalization for HF occurring more frequently than for myocardial infarction.
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Furthermore, patients hospitalized with HF have a higher subsequent mortality than those with myocardial infarction. 16 However, most current trials do now include adjudicated hospitalization for HF as a secondary endpoint.
Glycaemic control and heart failure
The incidence of cardiovascular outcomes in patients with diabetes and HF, including cardiovascular mortality and hospitalization for HF, is related to the severity of dysglycaemia [as indicated by the haemoglobin A 1c level (HbA 1c )]. 17, 18 However, there is little evidence to indicate that glycaemic control itself reduces the incidence of HF events in this population.
A recent study indicates that improved glycaemic control in patients with baseline mean HbA 1c of 10.3% resulted in improved indices of LV systolic function. 19 The absolute improvement of LV systolic function was related to the HbA 1c reduction. Both a decrease in body mass index (BMI) and treatment with metformin were additional independent predictors of improvement of LV systolic function. Yet, despite these encouraging experimental data, large clinical trials show that intensive glycaemic control has no impact on HF outcomes. A meta-analysis of randomized controlled studies ( Figure 1) shows that intensive glucose lowering compared with less stringent control had no impact on HF events, despite a reduction in myocardial infarction. 20 In a meta-analysis exploring the impact of glucose-lowering agents or strategies on cardiovascular outcomes, a total of 4% of patients experienced an HF event. 21 Overall, the study strategy or . 
Effects of individual glucose-lowering drug classes Insulin
Patients with type 2 diabetes receiving insulin have a higher incidence of HF and worse outcomes than those receiving only oral glucose-lowering agents. 22 However, insulin-treated patients tend to be older, and often receive insulin late in the course of their disease, when associated coronary heart disease, hypertension, and renal dysfunction are more likely to have become manifest. As no clinical trial addresses this question in an older population at risk of HF, it is unclear whether insulin treatment in these patients has any impact on cardiovascular disease outcomes.
Insulin has an antinatriuretic effect, which is dose-dependent and occurs at physiological insulin concentrations. 23 The sodium-retaining property of insulin is preserved even in the presence of insulin resistance in other tissues. 24 Fluid retention due to insulin is usually mild, but may contribute to the weight gain observed after initiation of insulin treatment, and precipitate HF in individuals with diastolic dysfunction.
In the BARI-2D study, 25 insulin provision with either insulin (61%) and/or sulphonylureas (52%) did not result in any significant difference in HF outcomes compared with a strategy of insulin sensitization with metformin (75%) and TZDs (62%), although peripheral oedema was more frequently seen in patients in the insulin sensitization group. The UKPDS study 26 reported no difference in HF between patients receiving insulin compared with those on sulphonylureas.
The ORIGIN trial 27 randomized 12 537 patients with dysglycaemia (either impaired glucose tolerance, impaired fasting glucose, or diabetes) to either basal insulin glargine or placebo. In this population of patients with either relatively mild diabetes or dysglycaemia and yet at high risk for cardiovascular events, there were no differences in cardiovascular outcomes, including hospitalization for HF [insulin glargine 4.9%, placebo 5.5%, hazard ratio (HR) 0.9, 95% CI 0.77-1.05].
In an observational study of 554 patients with severe HF, 132 had diabetes, of which 43 were receiving insulin. 28 One-year survival was 89.7% for the non-diabetic subjects, 85.8% for patients with diabetes not receiving insulin, and 62.1% for those taking insulin. Multivariate analysis showed that receiving insulin was an independent risk factor for 1-year mortality (HR 4.3, 95% CI 1. 69-10.94 ), yet diabetes not treated with insulin was not a risk factor (HR 0.95, 95% CI 0.31-2.93). This study probably did not eliminate all confounding variables that are associated with increased mortality in the patients receiving insulin. However, there are no controlled clinical trials that show the safety of insulin in Figure 1 Meta-analysis of trials evaluating the impact of intensive vs. standard glucose-lowering treatment on heart failure admission or death.
Reprinted with permission from Turnbull et al. 20 CI, confidence interval; HbA 1c , glycated haemoglobin; HR, hazard ratio.
patients at high risk of either developing HF or cardiovascular mortality.
Metformin
Metformin is currently considered the best first-line agent for glucose control in type 2 diabetes, consequent to relatively good tolerability, low cost, and a clinical trial (UKPDS) that suggested improved cardiovascular outcomes. 29 An administrative database analysis, examining treatment regimens in patients with diabetes and HF, indicated that metformin, alone or in combination, is associated with a lower mortality compared with sulphonylurea monotherapy. 30 A retrospective cohort study indicated a lower mortality in patients taking either metformin or a TZD after hospitalization for HF compared with patients not receiving an insulin sensitizer. 31 A systematic review of observational studies showed that metformin was at least as safe as other glucose-lowering agents in patients with HF, even in patients with severe LV impairment. 32 Furthermore, metformin was not associated with an increased risk of lactic acidosis in this population.
Sulphonylureas
Sulphonylureas improve glycaemic control by increasing insulin release. Although these drugs may cause both hypoglycaemia and weight gain, they do not cause sodium retention. There have been few randomized clinical trials assessing the cardiovascular disease safety of sulphonylurea agents. The UKPDS trial 26 evaluated the effect of a combination of insulin and sulphonylureas (with chlorpropamide, glibenclamide, or glipizide) compared with conventional dietary-based treatment in patients with newly diagnosed patients with diabetes. Heart failure was not increased in the group that received sulphonylureas compared with the conventional group (3.0% vs. 3.3%, HR 0.91, 95% CI 0.54-1.52).
Population-based observational studies 33 -35 provide divergent results. In the Saskatchewan Database study, 33 with metformin was not evident after adjustment for a history of ischaemic heart disease or use of a RAAS blocker. A study from the Cleveland Clinic 34 indicated that metformin had a lower HF risk than sulphonylureas (HR 0.76, 95% CI 0.64-0.91), even after adjustment for confounding variables. The risk of HF with sulphonylureas in this study was similar to the risk observed with TZDs. A UK general practice database 35 showed an 18-30% increased risk for HF with second-generation sulphonylureas when compared with metformin, even after adjustment for 25 variables.
The uncertainty about the cardiovascular safety, the risk of hypoglycaemia, and the associated weight gain have reduced the popularity of sulphonylureas in favour of agents with proven cardiovascular safety.
Thiazolidinediones
Thiazolidinediones such as rosiglitazone and pioglitazone were introduced with the hope that glycaemic control associated with improved insulin sensitivity, endothelial function, blood pressure, and lipid profile would slow the progression of atherosclerosis. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) clinical trial 36 with pioglitazone provided some support for this hypothesis, with a reduced secondary primary endpoint of cardiovascular death, myocardial infarction, and stroke (HR 0.84, 95% CI 0.72-0.90), despite no significant reduction in the primary endpoint that also included re-vascularization endpoints.
Therapy with TZD is associated with fluid retention and peripheral oedema in 3-5% of patients. When TZD treatment is combined with insulin, peripheral oedema is more frequent and observed in up to 15%. 37 The mechanism of TZD-induced oedema remains controversial. Sodium retention is probably due to PPAR (peroxisome proliferator-activated receptor )-mediated activation of a collecting duct sodium channel (ENaC), as well as activation of proximal tubular Na channels (NHE3). 38 However, some of the peripheral oedema observed with TZDs may be due to fluid extravasation due to peripheral arteriolar vasodilatation 39 that increase vascular permeability. 40 The TZDs probably have no direct impact on cardiac function. A study in normal subjects 41 comparing the impact of rosiglitazone with that of glyburide showed no change in LV mass or LVEF. Dargie et al. 42 reported in patients with NYHA class I-II HF that rosiglitazone treatment for 1 year had no impact on either LV systolic or diastolic function, despite the patients requiring increased diuretic usage and observing a modest increase in BNP.
An increased risk of HF is reported in clinical trials. In the DREAM trial, rosiglitazone was given to patients with impaired fasting glucose or impaired glucose tolerance, and no cardiovascular disease with the goal of preventing the development of type 2 diabetes. The incidence of HF in the rosiglitazone-treated patients was 0.5% and in the placebo group 0.1% (HR 7.03, 95% CI 1.60-30.9).
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In the PROactive study 36 that included patients with known cardiovascular disease, hospitalization for HF was increased 50% in the pioglitazone-treated patients (pioglitazone 6%, placebo 4%; P = 0.007) yet there was no increase in HF-related mortality.
The RECORD trial 44 was an open label study comparing rosiglitazone in addition to either metformin or a sulphonylurea with the combination of metformin and a sulphonylurea treatment. The occurrence of the primary endpoint of cardiovascular death or cardiovascular hospitalization did not differ in the two treatment groups. During the course of the study, more patients receiving rosiglitazone were prescribed loop diuretics. 45 Fatal and non-fatal HF events (HF admissions) were twice as frequent in patients receiving rosiglitazone (2.7% vs. 1.3%, HR 2.1, 95% CI 1.35-3.27), with more HF deaths in the rosiglitazone group (10 vs. 2). 45 Of the patients that survived the first hospitalization for HF, the subsequent mortality was high and similar in both treatment groups (30% vs. 28%).
The IRIS trial 46 administered pioglitazone to non-diabetic patients with ischaemic stroke and insulin resistance. More than 40% of participants had pre-diabetes as diagnosed by impaired fasting glucose (100-125 mg/dL) and >60% had pre-diabetes based on HbA 1c ≥5.7%. During the 5-year treatment period, there was a 24% reduction of the primary endpoint of stroke and myocardial infarction (HR 0.76. 95% CI 0.62-0.93). Neither investigator-reported HF (3.8% vs. 3.7%, P = 0.8) nor hospitalization for HF was increased (2.6% vs. 2.2% P = 0.35) by pioglitazone treatment. It should be noted, however, that HF was an exclusion in IRIS and the investigators developed a protocol for study drug dosage reduction if weight gain and/or oedema occurred unresponsive to conventional interventions. Both these aspects of IRIS may have reduce the likelihood of finding a HF signal.
A meta-analysis of seven studies with pioglitazone-or rosiglitazone-treated patients (n = 20 191) showed that HF outcomes were increased (HR 1.71, 95% CI 1.21-2.4) yet the risk of cardiovascular death was similar in TZD-and control-treated patients.
The American Diabetes Association (ADA) and the American Heart Association (AHA) in 2003 recommended that TZDs be used with caution in patients with NYHA class I-II HF and avoided in patients with class III and IV symptoms. 37 TZDs are currently used less frequently than in the past for the management of diabetes . 
Glucagon-like peptide 1 receptor agonists
Glucagon-like peptide 1 (GLP-1) is secreted in response to food ingestion by cells located in the distal intestine. GLP-1 receptors are expressed in the pancreas, cardiomyocytes, vascular endothelium, arterial smooth muscle cells, gastrointestinal tract, kidney, lung, breast, and central nervous system. In the pancreatic -cell, GLP-1 receptor stimulation results in glucose-dependent insulin secretion, but also suppresses glucagon release by the -cell. GLP-1 receptor agonists (RAs) are a newer class of glucose-lowering agents that result in additional potential cardiovascular benefits, that include weight loss and blood pressure, reduction with a low risk of hypoglycaemia. The increased heart rate observed in several GLP-1RA studies is of uncertain impact on cardiovascular disease outcomes. The GLP-1RAs have a myriad of effects in cardiovascular tissues that could be important in the prevention of HF. In cardiac myocytes, GLP-1RAs decrease apoptosis through cAMP/PKA/CRCB-mediated pathways. They also protect against oxidative stress injury. Although studies in isolated hearts suggested that GLP-1RAs decreased contractility, infusion of a GLP-1RA in an experimental animal model of HF resulted in improved indices of cardiac performance and myocardial glucose uptake. 47 In patients with HF, a 5-week infusion of a GLP-1RA improved LV function, functional status, and quality of life. 48 The FIGHT Study 49 showed that liraglutide administered daily by subcutaneous injection to patients who had recently been hospitalized with HF did not improve clinical outcomes whether or not they had diabetes. Neither mortality (liraglutide, 12% placebo 11%) nor hospitalization for HF (34% vs. 28%) was improved. The conclusion of the study was that liraglutide should not be used in patients with HF for the purpose of improving HF outcomes.
Clinical trials of GLP-1RAs in patients with diabetes at risk for adverse cardiac outcomes have shown divergent results. The ELIXA trial 50 was the first cardiovascular safety trial to report the impact of the GLP-1RA lixisenatide in patients who had sustained a myocardial infarction in the preceding 180 days. There was no significant impact on MACE outcomes over a 25-month period. A total of 22.3% of patients had a history of prior HF, yet lixisenatide had no impact on HF events, with 4.2% of placebo and 4.0% of the treatment group hospitalized for HF (HR 0.96, 95% CI 0.75-1.23).
The LEADER trial 51 evaluated the cardiovascular safety of the GLP-1RA liraglutide in 9340 subjects at high risk for cardiovascular disease outcomes. Prior cardiovascular disease was present in 72.4%, and 17.8% had prior HF. During the median follow-up period of 3.8 years, the primary outcome of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke was reduced by 13% by liraglutide (HR 0.87, 95% CI 0.78-0.97). Cardiovascular mortality was significantly reduced by 22% (HR 0.78, 95% CI 0.66-0.93). Non-fatal myocardial infarction and stroke were numerically less, but the differences did not achieve statistical significance. The pattern of cardiovascular benefits and their timing (occurring after 12-18 months) in LEADER appeared to suggest an effect of liraglutide on atherosclerosis.
Hospitalization for HF occurred in fewer liraglutide patients, but the difference was not statistically significant (HR 0.87, 95% CI 0.73-1.05, P = 0.14). However, fewer loop diuretics were initiated in the liraglutide-(6.5%) than in the placebo-(8.2%) treated patients (P = 0.01), perhaps indicating a lower incidence of less severe HF in the treatment group. Of the patients with a prior history of HF, the impact of liraglutide on the primary efficacy outcome was not statistically different from the patients with no history of HF.
Semaglutide, a long-acting once-weekly administered GLP-1RA, was also shown to result in a reduction of the primary cardiovascular MACE endpoint, as reported in an April 2016 top-line result announcement. 52 Details of the trial results will be available later in 2016.
Dipeptidyl peptidase-4 inhibitors
Glucagon-like peptide 1 is inactivated by the peptidase DPP-4. Inhibition of DPP-4 results in an increased availability of GLP-1, enhancing the incretin effect of post-prandial insulin release. However, DPP-4 has >50 identified substrates including BNP, erythropoietin, glucagon, vasoactive intestinal peptide, and vasostatin. 53 Thus, DPP-4 inhibition could impact many pathways including those involving cardiac signalling peptides, collagen turnover enzymes, and the sodium hydrogen exchanger in the renal proximal tubule. 54 The clinical outcomes of DPP-4 inhibition in patients at high risk of cardiovascular events has been reported from three randomized controlled clinical trials. The trials SAVOR-TIMI 53 55 (with saxagliptin), EXAMINE 56 (with alogliptin), and TECOS 10 (with sitagliptin) showed that over a 2-to 3-year period the study drug met non-inferiority criteria for the primary endpoint of MACE.
In the SAVOR-TIMI 53 study, hospitalization for HF was increased 27% by saxagliptin [HR 1.27, 95% CI . Heart failure occurred early within the first year of treatment ( Figure 2 ). Patients at greatest risk were those with prior HF, with an elevated baseline NT-proBNP, or chronic kidney disease. 57 However, saxagliptin treatment was not associated with either an increased incidence of peripheral oedema, weight gain, or increase in NT-proBNP. The EXAMINE study that included patients with recent myocardial infarction receiving alogliptin did not report the incidence of HF in the primary publication. 56 In a subsequent report, alogliptin was shown to be associated with a non-significant increase in hospitalization for HF (3.9% vs. 3.3%, HR 1.19, 95% CI 0.9-1.58). 58 Patients with higher NT-proBNP levels at baseline and a history of prior HF did not have a higher incidence of hospitalization for HF associated with alogliptin treatment. However, for patients with no history of HF, alogliptin significantly increased hospitalization for HF (2.2% vs. 1.3%, HR 1.76, 95% CI 1.07-2.90). Alogliptin had no impact on the composite event of cardiovascular death and hospitalization for HF (HR 1.00, 95% CI 0.82-1.21). 58 The TECOS study 10 that included 14 671 subjects with cardiovascular disease yet showed that sitagliptin did not increase hospitalization for HF (HR 1.00, 95% CI 0.83-1.20) during the 3-year period of the study. Overall hospitalization for HF was more likely in patients with a history of prior myocardial infarction, and prior HF. 59 Cardiovascular mortality and all-cause mortality after hospitalization for HF were similar and high in patients receiving sitagliptin and placebo (cardiovascular mortality 22.4% vs. 23.1%, all-cause mortality 29.8% vs. 28.8%).
The VIVIDD study (McMurray JJ., unpublished data, NCT00894868) investigated the effect of the DPP-4 inhibitor vildagliptin on echocardiographic measures of LV function in patients with symptomatic HF with an LVEF of <35% and poorly controlled diabetes. Worsening HF was not increased, and BNP levels decreased in both vildagliptin-and placebo-treated patients. Although the on-treatment LVEF was similar in the treatment and placebo groups, both LV systolic and diastolic volumes increased in the vildagliptin compared with placebo groups, suggesting impaired contractility.
The diverse HF outcomes observed in the three DPP-4 inhibitor trials could be due to differences in the patient populations, differences in the study protocol and patient care, intrinsic differences in the study drugs, or a play of chance in a secondary outcome. Two large administrative database studies have shown no increase in HF events with incretin-based treatment in patients with or without a prior history of HF. 60, 61 The FDA issued a Drug Safety Communication on 11 February 2014 stating that both saxagliptin and alogliptin may increase the risk of HF (http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm accessed on 25 June, 2016). The FDA recommended discontinuation, should a patient receiving these DPP-4 inhibitors develop HF. The communication did not issue any contraindications for the use of either agent, but did state that physicians should consider the risk and benefits of saxagliptin or alogliptin prior to initiating treatment in patients at a higher risk for HF.
Sodium-glucose co-transporter 2 inhibitors
Sodium-glucose co-transporters (SGLTs) facilitate transport of both glucose and sodium across cell membranes. Whilst the SGLT2 transporter is almost uniformly confined to the proximal renal tubule, the SGLT1 protein is more widely distributed and found in kidney, myocardium, intestine, and brain.
Inhibition of SGLT2 results in glycosuria of 70-80 g/day which is equivalent to a loss of 280-320 kcal/day. The glucose loss results in improved glycaemic control independent of insulin. SGLT2 inhibitors also block proximal tubular sodium reabsorption, resulting in a greater delivery of sodium to the distal tubular macula densa. The consequent tubular-glomerular feedback to the increased sodium results in afferent glomerular arterial constriction, reducing intraglomerular pressure and hyperfiltration. The net urinary sodium loss is modest and less than that achieved with thiazide diuretics. 62 However, unlike diuretics, SGLT2 inhibition results in a sustained reduction of plasma volume. 63 Consequent to increased glucagon and reduced insulin levels, SGLT2 inhibition results in a mild hyperketonaemia. The ketone body beta-hydroxybutyrate is a substrate for myocardial metabolism and is oxidized in preference to free fatty acids. fuel in preference to free fatty acids may improve myocardial energy generation, especially in stressed insulin-resistant myocardium, which has greater difficulty utilizing glucose. 64 The SGLT2 inhibitors have an overall beneficial effect on cardiovascular risk factors by reducing systolic blood pressure by 4-10 mmHg, weight by ∼2 kg (with a commensurate reduction of abdominal girth), HbA 1c by 0.6-0.9%, as well as reducing uric acid and triglycerides, and increasing HDL-cholesterol. LDL-cholesterol increases by ∼0.1 mmol/L, which is unlikely to be of clinical significance. The most common adverse effect is genital infection with candida species in an additional 5% of patients beyond that observed in a placebo-treated population.
Clinical trials to assess the cardiovascular disease safety of SLGT2 inhibitors include EMPA-REG OUTCOME (empagliflozin, reported in 2015 65 ), CANVAS (cangliflozin, due to report in 2017), and DECLARE-TIMI 58 (dapagliflozin due to report in 2019).
The EMPA-REG OUTCOME trial 65 included 7020 patients with type 2 diabetes (HbA 1c 7-10%), established cardiovascular disease, and estimated glomerular filtration rate (eGFR) >30 mL/min/ 1.73 m 2 . The patients were randomized to receive empagliflozin 10 mg, 25 mg, or placebo in equal numbers. Prior HF was reported in 10.2% of the population and 47% had a history of myocardial infarction. Almost half the patients were taking insulin, and 57% had known diabetes for >10 years. Renal dysfunction, with eGFR <60 mL/min/1.73 m 2 was present at baseline in 26%. Guidelinerecommended medical treatments with statins, ACE inhibitors or ARBs, and aspirin as well as target goals for blood pressure and LDL-cholesterol were achieved in a high proportion of patients.
After an observation period of 3 years, the study was terminated when the number of primary events exceeded 691. The primary MACE endpoint of cardiovascular death, non-fatal myocardial infarction, and stroke was reduced 14% by empagliflozin (HR 0.86, 95.02% CI 0.74-0.99, P = 0.04). Whereas cardiovascular mortality was reduced by 38% (HR 0.62, 95.02% CI 0.49-0.77, P < 0.001), empagliflozin did not substantially affect the incidence of non-fatal myocardial infarction or stroke. Empagliflozin also slowed the progression of kidney disease, and reduced important clinical renal events including the need for dialysis. 66 Empagliflozin reduced HF admissions and mortality by one-third ( Table 1 and Figure 3) , 11, 65 The benefit was seen in a wide range of subgroups of patients including those under or over 65 years of age, men and women, HbA 1c above or below 8.5%, BMI above or below 30 kg/m 2 , blood pressure above or below 140 mmHg, and GFR above or below 60 mL/min/1.73 m 2 .
11 A reduction of HF outcomes was observed with empagliflozin independent of Figure 3 Time to first hospitalization for heart failure or cardiovascular death in patients receiving empagliflozin or placebo in the EMPA-REG OUTCOME trial. Reprinted with permission from Fitchett et al. 11 CI, confidence interval; HR, hazard ratio. treatment at baseline with or without an ACE inhibitor, ARB, diuretics (including loop diuretics), and mineralocorticoids.
Patients admitted to hospital with HF had a high subsequent mortality, which is lower in the group receiving empagliflozin (13.5% vs. 24.2%). In the 10.5% of patients with a baseline history of prior HF, events were more frequent, yet empagliflozin treatment was associated with a numerically lower rate of both hospitalization for HF (10.4% vs. 12.3%, HR 0.75, 95% CI 0.48-1.19) and cardiovascular mortality (8.2% vs. 11.1%, HR 0.71, 95% CI 0.43-1.16). Subgroup analyses showed no heterogeneity of the treatment effect of empagliflozin on either hospitalization for HF or cardiovascular mortality in patients with or without a history of prior HF.
Prevention of HF events with empagliflozin is probably one of the modes by which cardiovascular mortality was reduced. The EMPA-REG OUTCOME trial was not designed to investigate the mechanisms of the observed benefit. However, since neither myocardial infarction, hospitalization for unstable angina, nor stroke event rates was affected by empagliflozin, it is unlikely that neither the reduction of mortality nor HF was mediated by vascular events. Moreover, the reduction of both mortality and HF occurred early, with benefit apparent after only 2-3 months of treatment. Such an early reduction in cardiovascular events has never been observed with either blood pressure reduction or glycaemic control. Yet an early reduction of mortality is seen in HF patients receiving RAAS antagonists or beta-blockade. SGLT2 inhibitors reduce intravascular volume 63 and the ∼4% increase in haematocrit observed in the EMPA-REG OUTCOME trial is probably due to a reduced plasma volume. A reduced intravascular volume in HF patients is associated with improved outcomes including survival. 67 The change in estimated plasma volume (calculated from the change of haematocrit and haemoglobin) after treatment of HF predicts cardiovascular events beyond traditional clinical factors. 68 It has also been proposed that metabolic changes with a modest increase in ketone bodies may favourably alter the energetics of myocardial substrate metabolism, especially in patients with abnormal myocardium and with insulin resistance. 
DPP4-i, dipeptidyl peptidase 4 inhibitor; GLP-1 A, glucagon-like peptide 1 agonist; HF, heart failure; MACE, major adverse cardiac event; SGLT2-i, sodium-glucose co-transporter 2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione.
It is possible that empagliflozin could have a widespread application in patients with HF or LV dysfunction. Clinical trials will now address the therapeutic benefit of empagliflozin in patients with established HF (with both preserved and reduced EF) and will also include individuals with and without diabetes (https://www .boehringer-ingelheim.com/press-release/jardiance-empagliflozinbe-studied-treatment-people-chronic-heart-failure).
Conclusions
Patients with diabetes are at a substantially increased risk both of dying from cardiovascular disease and of developing HF: a complication that further increases mortality and need for recurrent hospitalization. Heart failure outcomes are not reduced by tight Figure 4 The impact of glucose-lowering drugs on the incidence of hospitalization for heart failure (hazard ratio with 95% confidence intervals). DPP4i, dipeptidyl peptidase-4 inhibitor; GLP-1 A, glucagon-like peptide 1 agonist; SGLT2i, sodium-glucose co-transporter 2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione. 
Figure 5
Comparison of all-cause mortality reduction observed in heart failure trials with the EMPA-REG OUTCOME and LEADER 75 , f EMPA-REG OUTCOME 65 , g LEADER. 51 glucose control, but are more influenced by the choice of the glucose-lowering agent.
A summary of the cardiovascular impact of individual classes of glucose-lowering agents is shown in Table 2 . The GLP-1 agonist liraglutide did not significantly lower HF admissions. The SGLT2 inhibitor empagliflozin reduced the incidence of HF and cardiovascular mortality in patients with and without a prior history of HF. A summary of the impact of glucose-lowering agents on the incidence of HF is shown in Figure 4 . Empagliflozin provides a new therapeutic strategy that potentially will have a greater impact on cardiovascular mortality than current HF medications, including ACE inhibitors, ARBs, beta-adrenergic blockers, and neprilysin inhibition with sacubitril ( Figure 5) 51,65,69 -75 .
The choice of a glucose-lowering agent in patients with diabetes should be personalized to match the severity of hyperglycaemia, the risk of hypoglycaemia, concerns about weight gain, the presence of renal dysfunction, and the cost of treatment to the patient. Today it is necessary also to consider whether the patient has established cardiovascular disease and especially if they are at risk of developing HF. Recent clinical trials have provided us with efficacy and safety data in this population, which allows us to minimize risk but also, potentially, to improve outcomes. 
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